Imaging-based Phenotypic Screening is a extremely powerful and flexible approach to drug discovery and pre-clinical research.
Learn how imaging-based phenotypic assays work and what kind of information you can expect from working with us.
WHAT ARE SOME OF THE CHALLENGES ASSOCIATED WITH PHENOTYPIC ASSAYS?
The term “phenotypic assays” encompasses a vast range of technologies from simple bacterial viability to tumor formation in primate models. Our focus is in the middle of this range at the cellular level. Even with this constraint, there is an almost infinite number of assays that can be performed using imaging as a means to make measurements.
It is also worth noting that hybrid assays that combine phenotypic and target-centric readouts are commonly developed to address this concern. Learn more about this hybrid approach here >>>
However, as with all complex technology there are challenges that need to be overcome. Follow the links below to learn more about how we address these challenges in order to bring you the most relevant information on time and on budget.
Phenotypic assays that use imaging, specifically automated quantitative fluorescence microscopy or high content screening (HCS), bring their own set of challenges. We’ve tried to address how we tackle these challenges but if you have other concerns please contact us.